# Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment

> **NCT06664138** · PHASE4 · COMPLETED · sponsor: **Yeongseok Yun** · enrollment: 30 (actual)

## Conditions studied

- Schizophenia Disorder
- Major Depression Disorders
- Schizoaffective Disorder
- Bipolar

## Interventions

- **DRUG:** Remimazolam
- **DRUG:** Etomidate

## Key facts

- **NCT ID:** NCT06664138
- **Lead sponsor:** Yeongseok Yun
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-28
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06664138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06664138, "Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06664138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*